Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III Clinical Trial to Study the Immunogenicity, Tolerability, and Manufacturing Consistency of V503 (A Multivalent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] Vaccine) in Preadolescents and Adolescents (9 to 15 Year Olds) With a Comparison to Young Women (16 to 26 Year Olds)

Next Previous
Trial Profile

A Phase III Clinical Trial to Study the Immunogenicity, Tolerability, and Manufacturing Consistency of V503 (A Multivalent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] Vaccine) in Preadolescents and Adolescents (9 to 15 Year Olds) With a Comparison to Young Women (16 to 26 Year Olds)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 07 Sep 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs V 503 (Primary)
  • Indications Anal cancer; Cervical cancer; Condylomata acuminata; Head and neck cancer; Human papillomavirus infections; Vulvovaginal cancer
  • Focus Adverse reactions; Pharmacodynamics; Registrational
  • Sponsors Merck Sharp & Dohme Corp.

Most Recent Events

  • 05 Sep 2023 Results (n=1272) assessing immunogenicity and effectiveness through 10 years after the last vaccine dose published in the Pediatrics.
  • 05 Sep 2023 According to a Glyscend Therapeutics Media Release, 10-year long-term follow-up (LTFU) data published in the peer reviewed journal, Pediatrics.
  • 05 Sep 2023 Results presented in a Glyscend Therapeutics Media Release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top